Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To determine the objective response rate (complete plus partial) to the combination of
capecitabine (Xeloda) and oxaliplatin (Eloxatin) (XELOX) in patients with adenocarcinoma of
the small bowel and ampulla of Vater.
Secondary objectives include determining the toxicity, time-to-treatment failure, and overall
survival rates in patients treated with this combination.